George Sledge responds to Berry’s letter: Neoadjuvant doesn’t predict adjuvant in breast cancer and Berry’s rejoinder

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

As always, I both enjoyed and learned something interesting from Dr. Don Berry, one of the great biostatisticians of our era. I find, reading his analysis of ALTTO and NeoALTTO, much that I agree with. I am certainly no statistician, and must bow to his statistical analysis of ALTTO and NeoALTTO. And yet at the same time I think it misses the point. So I will beg to differ.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
George W. Sledge Jr.
Chief of oncology, Stanford University
Donald A. Berry
Professor of biostatistics, MD Anderson Cancer Center

YOU MAY BE INTERESTED IN

People of African ancestry (Black/African American) have some of the worst cancer incidence and greatest mortality, compared to white and other racial and ethnic populations in the U.S. On average, Black persons are 1.5 times more likely to have cancer and >2X more likely to die from cancer compared to whites. xxx:more
George W. Sledge Jr.
Chief of oncology, Stanford University
Donald A. Berry
Professor of biostatistics, MD Anderson Cancer Center

Login